Ipsen confirms FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC Read more
Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003 Read more
AbelZeta Pharma Announces Agreement with AstraZeneca to Co-Develop a novel Glypican 3 (GPC3) Armored CAR-T Therapy in China Read more
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE) and Plans to Expand Vepdegestrant Development Program Read more
AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies Read more
Bristol Myers Squibb’s Abecma Becomes First CAR T Approved for Use in Earlier Lines of Therapy for Patients with Relapsed or Refractory Multiple Myeloma in Japan Read more
FDA Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Read more
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer Read more